Rapid Urine Test Detects Early Kidney Injury
|
By LabMedica International staff writers Posted on 05 May 2014 |
|
Image: The NephroCheck Test cartridge and Astute140 Meter (Photo courtesy of Astute Medical).
A new test utilizes fluorescence immunoassay technology to detect and measure two biomarkers that reflect the risk of developing acute kidney injury (AKI).
The NephroCheck Test measures tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. Both are involved in G1 cell cycle arrest during the very early phases of cellular stress, and are robust measures of risk for AKI manifesting within the following 12-24 hours. TIMP-2 is an inhibitor of the matrix metalloproteinases (MMPs) that directly suppress the proliferation of endothelial cells. IGFBP-7 is involved in the regulation of tissue availability of insulin and IGFs, and stimulates cell adhesion implicated in epithelial cell-cycle arrest.
For the test, a sample of a patient’s urine is mixed with reagents onto a single-use cartridge inserted into the proprietary Astute140 Meter. The meter employs a sandwich immunoassay technique along with fluorescence detection technology to quantitatively measure the biomarker concentrations, combining them into a single numerical test result. Multiple levels of controls (internal, external, and electronic) are used to ensure reliable and accurate results in about 20 minutes. The NephroCheck Test and Astute140 Meter are products of Astute Medical (San Diego, CA, USA), and have received the European Community CE marking of approval.
“We believe the NephroCheck Test will be able to help physicians address one of the most costly, deadly, and confounding conditions affecting intensive care hospital patients,” said Chris Hibberd, CEO of Astute Medical. “With increasing constraints on healthcare spending, innovative tools such as the NephroCheck Test will be essential to ensuring that the right resources get to the right patients at the right time.”
AKI is a significant global health hazard that strikes up to seven percent of hospitalized patients. AKI often occurs in patients that are already suffering from myriad issues such as sepsis, trauma, surgery, or being treated with nephrotoxic drugs, further complicating diagnosis, while also increasing mortality rates.
Related Links:
Astute Medical
The NephroCheck Test measures tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. Both are involved in G1 cell cycle arrest during the very early phases of cellular stress, and are robust measures of risk for AKI manifesting within the following 12-24 hours. TIMP-2 is an inhibitor of the matrix metalloproteinases (MMPs) that directly suppress the proliferation of endothelial cells. IGFBP-7 is involved in the regulation of tissue availability of insulin and IGFs, and stimulates cell adhesion implicated in epithelial cell-cycle arrest.
For the test, a sample of a patient’s urine is mixed with reagents onto a single-use cartridge inserted into the proprietary Astute140 Meter. The meter employs a sandwich immunoassay technique along with fluorescence detection technology to quantitatively measure the biomarker concentrations, combining them into a single numerical test result. Multiple levels of controls (internal, external, and electronic) are used to ensure reliable and accurate results in about 20 minutes. The NephroCheck Test and Astute140 Meter are products of Astute Medical (San Diego, CA, USA), and have received the European Community CE marking of approval.
“We believe the NephroCheck Test will be able to help physicians address one of the most costly, deadly, and confounding conditions affecting intensive care hospital patients,” said Chris Hibberd, CEO of Astute Medical. “With increasing constraints on healthcare spending, innovative tools such as the NephroCheck Test will be essential to ensuring that the right resources get to the right patients at the right time.”
AKI is a significant global health hazard that strikes up to seven percent of hospitalized patients. AKI often occurs in patients that are already suffering from myriad issues such as sepsis, trauma, surgery, or being treated with nephrotoxic drugs, further complicating diagnosis, while also increasing mortality rates.
Related Links:
Astute Medical
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Steam Sterilizer
Hi Vac II Line
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Latest Clinical Chem. News
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- Blood Test Tracks Transplant Health Using Donor DNA
- New Blood Test Index Offers Earlier Detection of Liver Scarring
Channels
Molecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microbiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read more
Pathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Technology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more
